Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012, Article ID 703858, 9 pages
http://dx.doi.org/10.1155/2012/703858
Review Article

Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone

Department of Medical Oncology, G. Morris Dorrance Jr. Endowed Chair in Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Room C315, Philadelphia, PA 19111-2497, USA

Received 6 January 2012; Accepted 18 February 2012

Academic Editor: Thomas Rutherford

Copyright © 2012 Massimo Cristofanilli. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Desantis, R. Siegel, P. Bandi, and A. Jamal, “Breast cancer statistics, 2011,” CA: A Cancer Journal for Clinicians, vol. 61, no. 6, pp. 408–418, 2011. View at Publisher · View at Google Scholar
  2. ACS. Cancer Facts & Figures, 2011, http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf.
  3. V. Guarneri and P. Conte, “Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy,” Oncologist, vol. 14, no. 7, pp. 645–656, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. C. M. Perou, T. Sørile, M. B. Eisen et al., “Molecular portraits of human breast tumours,” Nature, vol. 406, no. 6797, pp. 747–752, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Sørlie, R. Tibshirani, J. Parker et al., “Repeated observation of breast tumor subtypes in independent gene expression data sets,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8418–8423, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Sotiriou, S. Y. Neo, L. M. McShane et al., “Breast cancer classification and prognosis based on gene expression profiles from a population-based study,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 18, pp. 10393–10398, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Perreard, C. Fan, J. F. Quackenbush et al., “Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay,” Breast Cancer Research, vol. 8, no. 2, article no. R23, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. A. T. Fojo and M. Menefee, “Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR),” Seminars in Oncology, vol. 32, no. 7, pp. S3–S8, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Geney, I. M. Ungureanu, D. Li, and I. Ojima, “Overcoming multidrug resistance in taxane chemotherapy,” Clinical Chemistry and Laboratory Medicine, vol. 40, no. 9, pp. 918–925, 2002. View at Google Scholar · View at Scopus
  10. E. K. Rowinsky, “The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents,” Annual Review of Medicine, vol. 48, pp. 353–374, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. C. A. Hudis and L. Gianni, “Triple-negative breast cancer: an unmet medical need,” The oncologist, vol. 16, supplement 1, pp. 1–11, 2011. View at Google Scholar
  12. G. A. Orr, P. Verdier-Pinard, H. McDaid, and S. B. Horwitz, “Mechanisms of Taxol resistance related to microtubules,” Oncogene, vol. 22, no. 47, pp. 7280–7295, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Hari, H. Yang, C. Zeng, M. Canizales, and F. Cabral, “Expression of class III β-tubulin reduces microtubule assembly and confers resistance to paclitaxel,” Cell Motility and the Cytoskeleton, vol. 56, no. 1, pp. 45–56, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Shalli, I. Brown, S. D. Heys, and A. C. Schofield, “Alterations of β-tubulin isotypes in breast cancer cells resistant to docetaxel,” FASEB Journal, vol. 19, no. 10, pp. 1299–1301, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Tommasi, A. Mangia, R. Lacalamita et al., “Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of β-tubulins,” International Journal of Cancer, vol. 120, no. 10, pp. 2078–2085, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Alli, V. B. Sharma, P. Sunderesakumar, and J. M. Ford, “Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase,” Cancer Research, vol. 69, no. 8, pp. 3589–3596, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Rottenberg, J. E. Jaspers, A. Kersbergen et al., “High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 44, pp. 17079–17084, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. H. E. Bryant, N. Schultz, H. D. Thomas et al., “Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase,” Nature, vol. 434, no. 7035, pp. 913–917, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Farmer, H. McCabe, C. J. Lord et al., “Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy,” Nature, vol. 434, no. 7035, pp. 917–921, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. J. O'Shaughnessy, C. Osborne, J. E. Pippen et al., “Iniparib plus chemotherapy in metastatic triple-negative breast cancer,” New England Journal of Medicine, vol. 364, no. 3, pp. 205–214, 2011. View at Publisher · View at Google Scholar
  21. J. O’Shaughnessy, L. S. Schwartzberg, M. A. Danso et al., “A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC),” Journal of Clinical Oncology, vol. 29, no. supplement 15s, abstract 1007, 2011. View at Google Scholar
  22. J. Cortes, J. O'Shaughnessy, D. Loesch et al., “Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study,” The Lancet, vol. 377, no. 9769, pp. 914–923, 2011. View at Publisher · View at Google Scholar
  23. C. J. Bode, M. L. Gupta, E. A. Reiff, K. A. Suprenant, G. I. Georg, and R. H. Himes, “Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules,” Biochemistry, vol. 41, no. 12, pp. 3870–3874, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. D. M. Bollag, P. A. McQueney, J. Zhu et al., “Epothilones, a new class of microtubule-stabilizing agents with a taxol- like mechanism of action,” Cancer Research, vol. 55, no. 11, pp. 2325–2333, 1995. View at Google Scholar · View at Scopus
  25. P. Giannakakou, R. Gussio, E. Nogales et al., “A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 6, pp. 2904–2909, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Chuang, N. Wiener, P. Christos et al., “Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary,” Annals of Oncology, vol. 21, no. 10, pp. 2075–2080, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. J. T. Hunt, “Discovery of Ixabepilone,” Molecular Cancer Therapeutics, vol. 8, no. 2, pp. 275–281, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Y. Lee, R. Borzilleri, C. R. Fairchild et al., “BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy,” Clinical Cancer Research, vol. 7, no. 5, pp. 1429–1437, 2001. View at Google Scholar · View at Scopus
  29. F. Y. Lee, A. Camuso, S. Castenada et al., “Preclinical studies of ixabepilone (BMS-247550) demonstrate optimal antitumor activity against both chemotherapy-sensitive and -resistant tumor types,” in Proceedings of the American Association of Cancer Research Annual Meeting, abstract 503, Washington, DC, USA, April 2006.
  30. M. Jordan, H. Miller, L. Ni et al., “The Pat-21 breast cancer model derived from a patient with primary taxol resistance recapitulates the phenotype of its origin, has altered beta-tubulin expression and is sensitive to ixabepilone,” in Proceedings of the American Association for Cancer Research Annual Meeting, abstract LB-280, Washington, DC, USA, April 2006.
  31. E. A. Perez, T. Patel, and A. Moreno-Aspitia, “Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer,” Breast Cancer Research and Treatment, vol. 121, no. 2, pp. 261–271, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Y. Lee, R. Smykla, K. Johnston et al., “Preclinical efficacy spectrum and pharmacokinetics of ixabepilone,” Cancer Chemotherapy and Pharmacology, vol. 63, no. 2, pp. 201–212, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Rivera, J. Lee, and A. Davies, “Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors,” Oncologist, vol. 13, no. 12, pp. 1207–1223, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Goodin, M. P. Kane, and E. H. Rubin, “Epothilones: mechanism of action and biologic activity,” Journal of Clinical Oncology, vol. 22, no. 10, pp. 2015–2025, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. Ixempra PI, IXEMPRA Kit (ixabepilone) for Injection, Full Prescribing Information, Bristol-Myers Squibb, 2010.
  36. E. A. Perez, G. Lerzo, X. Pivot et al., “Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine,” Journal of Clinical Oncology, vol. 25, no. 23, pp. 3407–3414, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. J. A. Sparano, E. Vrdoljak, O. Rixe et al., “Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane,” Journal of Clinical Oncology, vol. 28, no. 20, pp. 3256–3263, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. E. S. Thomas, H. L. Gomez, R. K. Li et al., “Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5210–5217, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Jassem, L. Fein, M. Karwal et al., “Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies,” Breast, vol. 21, no. 1, pp. 89–94, 2012. View at Publisher · View at Google Scholar
  40. F. Y. Lee, K. L. Covello, S. Castaneda et al., “Synergistic antitumor activity of ixabepilone (BMS-247550)plus bevacizumab in multiple in vivo tumor models,” Clinical Cancer Research, vol. 14, no. 24, pp. 8123–8131, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. H. S. Rugo, M. Campone, D. Amadori et al., “Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bevacizumab (pac/bev) as first-line therapy for metastatic breast cancer (MBC): final results,” Journal of Clinical Oncology, vol. 28, no. 15s, p. 1040, 2010. View at Google Scholar
  42. K. Miller, M. Wang, J. Gralow et al., “Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer,” New England Journal of Medicine, vol. 357, no. 26, pp. 2666–2676, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. J. W. Smith, S. J. Vukelja, A. C. Rabe et al., “Final results of a phase II randomized trial of weekly or every-3-week ixabepilone in metastatic breast cancer (MBC),” in Proceedings of the Breast Cancer Symposium, Abstract 268, 2010.
  44. S. Moulder, H. Li, M. Wang et al., “A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial,” Breast Cancer Research and Treatment, vol. 119, no. 3, pp. 663–671, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. N. Robert, B. Leyland-Jones, L. Asmar et al., “Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2—overexpressing metastatic breast cancer,” Journal of Clinical Oncology, vol. 24, no. 18, pp. 2786–2792, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Awada, M. J. Piccart, S. F. Jones et al., “Phase i dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy,” Cancer Chemotherapy and Pharmacology, vol. 63, no. 3, pp. 417–425, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Denduluri, J. A. Low, J. J. Lee et al., “Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes,” Journal of Clinical Oncology, vol. 25, no. 23, pp. 3421–3427, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. J. A. Low, S. B. Wedam, J. J. Lee et al., “Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer,” Journal of Clinical Oncology, vol. 23, no. 12, pp. 2726–2734, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Roché, L. Yelle, F. Cognetti et al., “Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy,” Journal of Clinical Oncology, vol. 25, no. 23, pp. 3415–3420, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. E. Thomas, J. Tabernero, M. Fornier et al., “Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer,” Journal of Clinical Oncology, vol. 25, no. 23, pp. 3399–3406, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Plummer, P. Woll, D. Fyfe et al., “A phase i and pharmacokinetic study of lxabepilone in combination with carboplatin in patients with advanced solid malignancies,” Clinical Cancer Research, vol. 14, no. 24, pp. 8288–8294, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. S. M. Tolaney, J. Najita, W. Chen et al., “A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer,” Cancer Research, vol. 69, abstract 3137, 2009. View at Google Scholar
  54. J. Baselga, M. Zambetti, A. Llombart-Cussac et al., “Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer,” Journal of Clinical Oncology, vol. 27, no. 4, pp. 526–534, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. H. D. Bear, S. Anderson, R. E. Smith et al., “Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27,” Journal of Clinical Oncology, vol. 24, no. 13, pp. 2019–2027, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Wardley, “Capecitabine: expanding options for the treatment of patients with early or locally advanced breast cancer,” Oncologist, vol. 11, no. 1, pp. 20–26, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. N. Wolmark, J. Wang, E. Mamounas, J. Bryant, and B. Fisher, “Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18,” Journal of the National Cancer Institute Monographs, no. 30, pp. 96–102, 2001. View at Google Scholar · View at Scopus
  58. K. J. Rosenberg, J. L. Ross, H. E. Feinstein, S. C. Feinstein, and J. Israelachvili, “Complementary dimerization of microtubule-associated tau protein: implications for microtubule bundling and tau-mediated pathogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 21, pp. 7445–7450, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Felgner, R. Frank, J. Biernat et al., “Domains of neuronal microtubule-associated proteins and flexural rigidity of microtubules,” Journal of Cell Biology, vol. 138, no. 5, pp. 1067–1075, 1997. View at Publisher · View at Google Scholar · View at Scopus
  60. M. C. Choi, U. Raviv, H. P. Miller et al., “Human microtubule-associated-protein tau regulates the number of protofilaments in microtubules: a synchrotron X-ray scattering study,” Biophysical Journal, vol. 97, no. 2, pp. 519–527, 2009. View at Publisher · View at Google Scholar · View at Scopus